Healthtech Capital Readiness Begins Before the Pitch

Healthtech companies rarely lose rounds in the meeting. They lose them in the two weeks after it, when a diligence request surfaces something the team has not looked at closely: a convertible note with terms nobody modelled, a reimbursement assumption resting on a code that does not apply, an evidence plan that cannot support the claim in the deck.

Readiness is not a pitch skill. It is a standing operating state, and it has to exist before the first serious conversation.

Cap table and data room integrity

The unglamorous layer is the one that kills timelines. Before an investor process begins, the following should be true and verifiable in an afternoon.

• Every instrument on the cap table is documented, signed, and reconciled to the same version of truth.
• Option pool, promises made verbally, and advisor grants are reflected — not remembered.
• IP assignment is complete for every founder, employee, contractor, and university relationship.
• Grant and award agreements are in the room, with any march-in, data rights, or subcontract obligations flagged rather than buried.
• Financials reconcile to the bank, and the burn model matches the milestone plan being presented.

Nothing damages a process faster than a correction to a number the investor has already circulated internally.

Regulatory, reimbursement, and evidence assumptions

Three assumptions carry most of the valuation in healthtech, and they are frequently held loosely: the regulatory pathway and its evidence requirement, the reimbursement or payment mechanism, and the clinical or operational evidence that will convince a buyer rather than a regulator.

Each should be written as a claim with a basis and a named risk. A sophisticated investor is not looking for certainty here; they are looking for whether the team knows precisely which assumption is load-bearing and what would falsify it.

Match sources to milestones

The strongest healthtech raises show a stack where each source has a job. Non-dilutive capital carries the technical and early clinical de-risking. A strategic or channel partner validates delivery. The equity round funds the commercial build after the expensive uncertainty has been retired.

Companies that skip this arrive asking equity to pay for risk reduction — the most expensive way to buy it.

Treat investor exposure as diligence, not pitch practice

The most useful preparation is not rehearsal. It is early, structured exposure to investors operating in diligence mode, with permission to break the story.

The University City Science Center reports that its Capital Readiness Program, built around live investor diligence rather than pitch practice, has run eleven cohorts supporting 110 companies, with alumni reporting more than $173M in healthcare innovation capital. That structure works because it surfaces the defects while they are still cheap to fix.

Those outcomes are reported by the program operator and reflect program-level results. They are not represented as solely attributable to Forged Catalyst.

Procurement and security are capital constraints

In health systems, the buyer's constraints are the company's constraints. Security review, data handling posture, integration requirements, and procurement tempo determine when revenue can actually start — which determines what the round has to fund.

• Medical device and connected-health cybersecurity expectations should be designed in, not retrofitted during a sale.
• Health system procurement cycles are long enough that a pilot signed late in the year may not produce revenue in the model year the round assumes.
• Evidence a clinician will act on and evidence a regulator will accept are different artifacts; budget for both.

Companies that internalize this stop presenting an optimistic revenue curve and start presenting a procurement-aware one. Investors reward the second, because it is the one that survives their own portfolio experience.